Citius Pharmaceuticals, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Citius Pharmaceuticals is in Stage 4, the downtrend phase, now in week 2 (since Oct 14, 2026). It closed at $0.37, 79.6% below its 52-week high and below its 200-day average, which is falling.

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. More about the company

$0.37

-8.37% today

$10.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CTXR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S4 43w

S4 16w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 7w → S4 10w → S1 6w → S3 1w → S4 1w → S3 2w → S4 7w → S1 6w → S4 43w → S1 11w → S4 5w → S1 4w → S3 5w → S4 16w → S1 3w → S4 14w → S1 8w → S4 1w current

Total tracked: 166 weeks across 19 stage runs.

CTXR among Biotechnology456th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…456	CTXRCitius Pharmaceuticals, Inc.	Stage 4 · wk 2	12	−34.8%

vs 52W High

-79.6%

$0.37 lo$1.82 hi

79.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-44.5%

200 DMA: $0.67 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.87x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-34.8%

-28.7%

-60.2%

YTD

-56.3%

-77.9%

Scan Membership

Breakout Watch

Latest: 2023-01-30

5 appearances in last 60 days. First seen: 2020-02-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.87x

2026-10-21S4

Wk 2 · Vol 0.98x

2026-10-20S4

Wk 1 · Vol 0.48x

2026-10-19S4

Wk 1 · Vol 1.35x

2026-10-16S4

Wk 1 · Vol 0.34x

2026-10-15S4

Wk 1 · Vol 0.59x

2026-10-14S41→4

Wk 1 · Vol 0.45x

2026-10-13S1

Wk 8 · Vol 0.37x

2026-10-12S1

Wk 8 · Vol 0.23x

2026-10-09S1

Wk 7 · Vol 0.26x

2026-10-08S1

Wk 7 · Vol 0.23x

2026-10-07S1

Wk 7 · Vol 0.28x

Moving averages & range

50 DMA

$0.55

200 DMA

$0.67

52W High

$1.82

52W Low

$0.37

5D Low

$0.37

Resistance levels (recent highs)

20d High

$0.58

60d High

$0.78

120d High

$0.78

250d High

$1.82

Next resistance

+56.1%

to 20d High

ROE

-81.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

Citius Pharmaceuticals: quick answers

What stage is Citius Pharmaceuticals in?

As of Oct 22, 2026, Citius Pharmaceuticals (CTXR) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 14, 2026 and is in week 2. What the four stages mean

Is Citius Pharmaceuticals in an uptrend?

No. Citius Pharmaceuticals is in a Stage 4 downtrend. It trades 44.5% below its 200-day average, which is falling.

How far is Citius Pharmaceuticals from its 52-week high?

Citius Pharmaceuticals closed at $0.37 on Oct 22, 2026, 79.6% below its 52-week high of $1.82. Its 52-week low is $0.37.

How has Citius Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Citius Pharmaceuticals is down 77.9% over the past year and down 56.3% so far in 2026.

Which sector and industry is Citius Pharmaceuticals in?

Citius Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.